CONMED CORPORATION (CNMD) Gross Margin
- Gross margin · 12 months: Value 55.79%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 55.79% | Gross profit / revenue. Period ending 2026-06-30. $765.31M ÷ $1.37B × 100 ≈ 55.79% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 765.31M USD | Gross Profit |
| Revenue | 1.37B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 606.35M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $765.31M | $1.37B | $606.35M | 55.79% |
| 2025-12-31 | $750.48M | $1.37B | $624.25M | 54.59% |
| 2025-09-30 | $730.53M | $1.35B | $616.94M | 54.22% |
| 2025-06-30 | $743.41M | $1.33B | $582.84M | 56.05% |
| 2025-03-31 | $738.82M | $1.32B | $577.18M | 56.14% |
| 2024-12-31 | $733.03M | $1.31B | $573.98M | 56.08% |
| 2024-09-30 | $716.86M | $1.29B | $571.25M | 55.65% |
| 2024-06-30 | $705.93M | $1.28B | $570.07M | 55.32% |
| 2024-03-31 | $692.89M | $1.26B | $568.66M | 54.92% |
| 2023-12-31 | $676.25M | $1.24B | $568.50M | 54.33% |
| 2023-09-30 | $625.93M | $1.17B | $542.63M | 53.56% |
| 2023-06-30 | $609.49M | $1.14B | $529.59M | 53.51% |
| 2023-03-31 | $590.58M | $1.10B | $508.04M | 53.76% |
| 2022-12-31 | $571.25M | $1.05B | $474.23M | 54.64% |
| 2022-09-30 | $595.24M | $1.07B | $473.34M | 55.70% |
| 2022-06-30 | $585.93M | $1.04B | $456.38M | 56.21% |
| 2022-03-31 | $575.58M | $1.02B | $444.71M | 56.41% |
| 2021-12-31 | $568.04M | $1.01B | $442.60M | 56.21% |
| 2021-09-30 | $547.69M | $989.49M | $441.80M | 55.35% |
| 2021-06-30 | $539.08M | $978.50M | $439.42M | 55.09% |
| 2021-03-31 | $469.59M | $881.13M | $411.54M | 53.29% |
| 2020-12-31 | $460.30M | $862.46M | $402.16M | 53.37% |
| 2020-09-30 | $466.76M | $874.50M | $407.74M | 53.37% |
| 2020-06-30 | $463.18M | $870.25M | $407.08M | 53.22% |
| 2020-03-31 | $522.44M | $950.73M | $428.29M | 54.95% |
| 2019-12-31 | $524.72M | $955.10M | $430.38M | 54.94% |
| 2019-09-30 | $515.39M | $932.67M | $417.28M | 55.26% |
| 2019-06-30 | $495.91M | $901.39M | $405.48M | 55.02% |
| 2019-03-31 | $480.99M | $875.95M | $394.96M | 54.91% |
| 2018-12-31 | $469.11M | $859.63M | $390.52M | 54.57% |
| 2018-09-30 | $460.41M | $839.75M | $379.33M | 54.83% |
| 2018-06-30 | $452.33M | $827.56M | $375.22M | 54.66% |
| 2018-03-31 | $440.71M | $811.89M | $371.18M | 54.28% |
| 2017-12-31 | $431.04M | $796.39M | $365.35M | 54.12% |
| 2017-09-30 | $414.04M | $777.93M | $363.89M | 53.22% |
| 2017-06-30 | $412.70M | $772.61M | $359.90M | 53.42% |
| 2017-03-31 | $410.48M | $768.89M | $358.41M | 53.39% |
| 2016-12-31 | $408.33M | $763.52M | $355.19M | 53.48% |
| 2016-09-30 | $403.75M | $750.44M | $346.70M | 53.80% |
| 2016-06-30 | $396.08M | $734.84M | $338.75M | 53.90% |
| 2016-03-31 | $387.16M | $722.43M | $335.27M | 53.59% |
| 2015-12-31 | $381.70M | $719.17M | $337.47M | 53.08% |
| 2015-09-30 | $383.36M | $723.15M | $339.80M | 53.01% |
| 2015-06-30 | $386.23M | $728.93M | $342.70M | 52.99% |
| 2015-03-31 | $393.76M | $736.05M | $342.30M | 53.50% |
| 2014-12-31 | $404.06M | $740.05M | $336.00M | 54.60% |
| 2014-09-30 | $411.42M | $748.49M | $337.07M | 54.97% |
| 2014-06-30 | $410.43M | $752.79M | $342.36M | 54.52% |
| 2014-03-31 | $412.32M | $757.63M | $345.31M | 54.42% |
| 2013-12-31 | $412.42M | $762.70M | $350.29M | 54.07% |
| 2013-09-30 | $408.31M | $760.51M | $352.20M | 53.69% |
| 2013-06-30 | $410.80M | $763.14M | $352.34M | 53.83% |
| 2013-03-31 | $407.61M | $759.84M | $352.22M | 53.64% |
| 2012-12-31 | $405.84M | $767.14M | $361.30M | 52.90% |
| 2012-09-30 | $395.01M | $751.47M | $356.46M | 52.56% |
| 2012-06-30 | $388.41M | $742.40M | $354.00M | 52.32% |
| 2012-03-31 | $380.13M | $735.94M | $355.81M | 51.65% |
| 2011-12-31 | $374.93M | $725.08M | $350.14M | 51.71% |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | $369.31M | $720.81M | (m) | 51.23% |
| 2010-12-31 | $365.38M | $713.72M | $348.34M | 51.19% |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2010-03-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | $337.33M | $694.74M | $357.41M | 48.56% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |